wp-mail-logging domain was triggered too early. This is usually an indicator for some code in the plugin or theme running too early. Translations should be loaded at the init action or later. Please see Debugging in WordPress for more information. (This message was added in version 6.7.0.) in /home/stabioph/public_html/wp-includes/functions.php on line 6114
+65 3158 9940
1300 798 820
+64 9801 0299
ST has featured in the latest MedTech Sector report published by financial services and corporate advisory firm RSM. Turn to pages 16 and 17 where CEO Carlo Montagner discusses our business model, licensing strategy and future plans. Click on the magazine below to read the article.
The following story appeared on 7NEWS August 2023. When nature delivers new medicine: Our soft tissue sarcoma therapy Yondelis® (trabectedin) has this month been listed on the Pharmaceutical Benefits Scheme for patients with advanced liposarcoma and leiomyosarcoma, but you may be surprised where scientists originally sourced this novel compound.
Pharma Dispatch 20 January 2023 New Zealand Approval for Specialised Therapeutics’ Cancer Therapy Specialised Therapeutics Asia has announced that its therapy to treat rare gastrointestinal stromal tumours, QINLOCK (ripretinib), has been approved for use in New Zealand and will now be considered for funding by PHARMAC. The regulator, Medsafe, has approved QINLOCK for
PHARMA IN FOCUS By Tiffany Walker 20 January 2023 ST Notches Another Win Specialised Therapeutics (ST) has scored approval for Qinlock in New Zealand, marking the second of five regions that the company has rights to commercialise the advanced gastrointestinal stromal tumour (GIST) treatment. The Singapore headquartered company was established to commercialise new therapies and
At homegrown pharma company Specialised Therapeutics, 82 per cent of employees are women, three in every four employees is aged over 40, and nine of the 12 executive team members is female.
Age, gender, and ethnicity are not a consideration when hiring, says CEO Carlo Montagner, who instead employs people that best fit with the values of the business he co-founded with his wife, Bozena Zembrzuski.
PHARMA IN FOCUS By Christine Spiteri 10 February 2022 Who’s Mandated a Third Jab? Specialised Therapeutics has made a third COVID-19 vaccine compulsory for all staff, to ensure a safe office environment for employees returning to work. The team was told on Christmas Eve last year that booster shots for those who were eligible would
PHARMA IN FOCUS By Christine Spiteri 21 December 2021 Job Boom Hits Growing Pharma Specialised Therapeutics is experiencing a mini-jobs boom, with the company’s growing portfolio and expansion across South East Asia requiring a boost to its workforce. The company currently has a staff of about 40 but is actively looking to fill five new
The following tweet and story appeared on 7NEWS November 2021. A new treatment is now within reach for sufferers of a rare and incurable cancer. The new tablet has been listed on the PBS, helping buy patients precious time. Click here to watch: https://youtu.be/bPUTlbcamVo @AKunowski #7NEWS
Australian Financial Review By Carrie LaFrenz 15 March 2021 Latitude Offers Payment Plans for $5000 Breast Cancer Test When Carlo Montagner – the founder of Australia’s largest independent specialist pharmaceutical company – was buying a new sofa at Harvey Norman he saw a Latitude Financial Group sign, and it sparked an idea. A year on, his
BioPharma Dispatch 15 March 2021 Australians Will Need to ‘Reconcile Themselves to this New Reality’ STA’s Carlo Montagner says the company’s finance arrangement with Latitude Finance to support patient access to a cancer recurrence diagnostic is unfortunate but that Australians need to “reconcile themselves to this new reality” while government funding remains such a challenge.